A detailed history of Crossmark Global Holdings, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 7,706 shares of TGTX stock, worth $268,708. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,706
Previous 5,728 34.53%
Holding current value
$268,708
Previous $225,000 23.11%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 08, 2025

BUY
$33.37 - $45.51 $66,005 - $90,018
1,978 Added 34.53%
7,706 $277,000
Q1 2025

Apr 29, 2025

BUY
$27.67 - $42.99 $158,493 - $246,246
5,728 New
5,728 $225,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.07B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Crossmark Global Holdings, Inc. Portfolio

Follow Crossmark Global Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.